Tritace in renal disease

Tritace (ramipril) is now licensed for the treatment of incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, or manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥3g/day.

View Tritace drug record

Further information: Sanofi-aventis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MIMS launches Respiratory and Allergy Learning workshops 2019

MIMS launches Respiratory and Allergy Learning workshops 2019

Join us for the MIMS Workshops Respiratory and Allergy...

Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Widespread false diagnosis of COPD is exposing patients to unnecessary medication risks, study suggests
Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.